Bipolar mood disorder and treatment-resistant depression by Rybakowski, Janusz K
MEETING ABSTRACT Open Access




st International Congress on Neurobiology and Clinical Psychopharmacology and European
Psychiatric Association Conference on Treatment Guidance
Thessaloniki, Greece. 19-22 November 2009
Two lines of evidence point to the relationship between
bipolar mood disorder and treatment-resistant depres-
sion. First, the frequency of suboptimal response to anti-
depressant drugs is significantly higher in bipolar than
in unipolar mood disorder. Secondly, the first and the
second generation mood stabilizing drugs are efficacious
for augmentation of antidepressants in treatment-
resistant depression.
Short-term non-response to antidepressant drugs has
been significantly higher in bipolar and in unipolar
mood disorder. A significant percentage of unipolar
depressed patients resistant to antidepressant drugs
reaches a diagnosis of bipolarity during a specific
screening or during follow-up. In the Polish all-country
DEP-BI study including 880 depressed outpatients trea-
ted with psychiatrists, it was found that the percentage
of treatment-resistant depression was significantly higher
in bipolar than in unipolar mood disorder, especially so,
in bipolar spectrum disorder where the features of bipo-
larity are most easy to overlook. Recent Polish TRES-
DEP study included 1051 depressed patients (569 with
treatment-resistant and 482 with treatment non-resis-
tant depression). Using Hypomania Check List-32
(HCL-32) scale, it has been found that the percentage of
≥ 14 score on HCL-32, indicating bipolarity, was signifi-
cantly higher in patients with treatment resistant than in
treatment-nonresistant depression (44% vs 30%,
respectively).
Lithium, the prototypic mood stabilizer, has been the
most frequent modality used for the augmentation of
antidepressants in treatment-resistant depression, and
the efficacy of lithium in this respect has been con-
firmed by a number of meta-analyses. Our study has
shown that such effect of lithium is significantly better
in bipolar than in unipolar depression. Out of the first
generation antidepressant drugs, also some efficacy of
carbamazepine, and to less extent, valproate, has been
found for the augmentation of antidepressants. Lamotri-
gine, new generation anticonvulsant and mood-stabili-
zer, demonstrated its antidepressant efficacy both during
acute episode and in prophylaxis of depression in bipo-
lar illness. It has been also effective for augmentation of
antidepressant drugs in treatment-resistant depression.
In our study we found that the overall efficacy of lamo-
trigine was similar to that of lithium, however, both
drugs were more efficacious for augmentation of venla-
faxine than paroxetine.
In recent years, there have been numerous studies on
the efficacy of second generation antipsychotic drugs
(some of them can be qualified also as second genera-
tion mood stabilizers) for the augmentation of antide-
pressants in treatment-resistant depression. While the
clear antidepressant effect of quetiapine as monotherapy
has been demonstrated, the majority of second genera-
tion antipsychotics proved their efficacy in augmentation
of antidepressants in treatment-resistant depression, and
aripirazole, obtained an official approval for such
indication.
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